According to recent data, some NSCLC patients with alterations in BRAF, MET, RET or HER2 may benefit from ICIs in a similar way as unselected NSCLC patients, but larger prospective studies are needed [17]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.